Tag - MDCX

Developments

Medicus submits study design to FDA for Teverelix in AURr

Medicus Pharma (NASDAQ: MDCX) has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, its investigational GnRH antagonist, for the prevention of recurrent acute urinary retention (AURr) in men...

April 6, 2026

Executive Moves

Medicus appoints Andrew Smith as COO

Medicus Pharma (NASDAQ: MDCX) has announced the appointment of Andrew Smith as chief operating officer (COO). A seasoned leader in asset management and financial operations with more than three decades of experience, Mr...

June 23, 2025

Developments

Medicus provides update on Phase 2 study of D-MNA in BCC

Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of...

February 14, 2025

Tag - MDCX

Medicus submits study design to FDA for Teverelix in AURr

Medicus appoints Andrew Smith as COO

Medicus provides update on Phase 2 study of D-MNA in BCC

Subscribe